We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters (WAT) BioAccord System to Expand Portfolio Offerings
Read MoreHide Full Article
Waters Corporation (WAT - Free Report) launched an integrated high-resolution liquid chromatography mass spectrometry (LC-MS) system, namely the Waters BioAccord System with ACQUITY Premier.
The BioAccord System improves analyte recovery and assay-to-assay reproducibility for seamless monitoring of attributes of biotherapeutics as well as helps scientists to get faster information about the samples.
It features the MaxPeak High Performance Surface technology that provides many benefits like increasing the level of detector sensitivity, improved peak shapes, greater peak capacity and reproducibility as well as reducing the requirement of system passivation.
It also features a SmartMS-enabled ACQUITY RDa mass detector that offers guided workflows for seamless deployment.
The recent product is expected to expand the company’s reach to scientists and analysts. This might also contribute to top-line growth in the upcoming period.
With the recent move, Waters has positioned itself well to expand its presence in the growing LC-MS market.
This booming market is backed by increasing research and development expenditure in the healthcare sector as well as the rising number of clinical trials.
Major pharmaceutical and biotechnology companies are expanding their product offerings. This also acts as a key driver for market growth.
According to a report by 360 Market Updates, the global LC-MS market is expected to hit $3.39 billion by 2026, witnessing a CAGR of 6.9% between 2021 and 2026.
Additionally, a report by Industry Research indicates that the market is likely to hit $2.93 billion by 2027, registering a CAGR of 4.9% from 2021 to 2027.
Expanding Product portfolio
The latest move bodes well for Waters’ strong efforts to expand the product portfolio consisting of chromatography consumables and columns, mass spectrometry systems, laboratory automation, integrated solutions, and others.
Apart from the recent launch, it unveiled the TRIOS AutoPilot software that automates thermal analysis workflows, reduces errors, maintains product quality and enhances the productivity of operations.
It also introduced the liquid chromatography system named Waters Arc Premier System that is optimized for chromatographic separations on 2.5-3.5 micron columns.
In addition, it unveiled a high-resolution mass spectrometer named SELECT SERIES Multi Reflecting Time-of-Flight technology with desorption electrospray ionization and matrix-assisted laser desorption ionization imaging sources for applications in pharmaceutical, biomedical, natural products, and materials research.
Further, it introduced Otto SPEcialist Positive Pressure Manifold, which provides more reliability and reproducibility of solid phase extraction with greater efficiency,ideal for various pharmaceutical, biopharmaceutical, food and beverage as well as environmental applications.
We believe that these endeavors will continue to benefit Waters in gaining strong momentum in various end-markets served.
Image: Shutterstock
Waters (WAT) BioAccord System to Expand Portfolio Offerings
Waters Corporation (WAT - Free Report) launched an integrated high-resolution liquid chromatography mass spectrometry (LC-MS) system, namely the Waters BioAccord System with ACQUITY Premier.
The BioAccord System improves analyte recovery and assay-to-assay reproducibility for seamless monitoring of attributes of biotherapeutics as well as helps scientists to get faster information about the samples.
It features the MaxPeak High Performance Surface technology that provides many benefits like increasing the level of detector sensitivity, improved peak shapes, greater peak capacity and reproducibility as well as reducing the requirement of system passivation.
It also features a SmartMS-enabled ACQUITY RDa mass detector that offers guided workflows for seamless deployment.
The recent product is expected to expand the company’s reach to scientists and analysts. This might also contribute to top-line growth in the upcoming period.
Waters Corporation Price and Consensus
Waters Corporation price-consensus-chart | Waters Corporation Quote
LC-MS Market Prospects
With the recent move, Waters has positioned itself well to expand its presence in the growing LC-MS market.
This booming market is backed by increasing research and development expenditure in the healthcare sector as well as the rising number of clinical trials.
Major pharmaceutical and biotechnology companies are expanding their product offerings. This also acts as a key driver for market growth.
According to a report by 360 Market Updates, the global LC-MS market is expected to hit $3.39 billion by 2026, witnessing a CAGR of 6.9% between 2021 and 2026.
Additionally, a report by Industry Research indicates that the market is likely to hit $2.93 billion by 2027, registering a CAGR of 4.9% from 2021 to 2027.
Expanding Product portfolio
The latest move bodes well for Waters’ strong efforts to expand the product portfolio consisting of chromatography consumables and columns, mass spectrometry systems, laboratory automation, integrated solutions, and others.
Apart from the recent launch, it unveiled the TRIOS AutoPilot software that automates thermal analysis workflows, reduces errors, maintains product quality and enhances the productivity of operations.
It also introduced the liquid chromatography system named Waters Arc Premier System that is optimized for chromatographic separations on 2.5-3.5 micron columns.
In addition, it unveiled a high-resolution mass spectrometer named SELECT SERIES Multi Reflecting Time-of-Flight technology with desorption electrospray ionization and matrix-assisted laser desorption ionization imaging sources for applications in pharmaceutical, biomedical, natural products, and materials research.
Further, it introduced Otto SPEcialist Positive Pressure Manifold, which provides more reliability and reproducibility of solid phase extraction with greater efficiency,ideal for various pharmaceutical, biopharmaceutical, food and beverage as well as environmental applications.
We believe that these endeavors will continue to benefit Waters in gaining strong momentum in various end-markets served.
Zacks Rank & Other Stocks to Consider
Currently, Waters carries a Zacks Rank #2 (Buy).
Other similar-ranked stocks in the broader technology sector include Advanced Micro Devices (AMD - Free Report) , Dropbox (DBX - Free Report) and ASML Holding (ASML - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Long-term earnings growth rates for Advanced Micro Devices, Dropbox, and ASML Holding are currently projected at 44.6%, 40.9%, and 33.5% respectively.